Atossa Therapeutics shares are trading higher after the company provided a five-year on a breast cancer patient who received neoadjuvant and adjuvant (Z)-endoxifen therapy.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.